Travere Therapeutics (TVTX) cash on hand

Cash · fiscal 2025
$322.80M

Travere Therapeutics (TVTX) held cash of $322.80M at the end of fiscal 2025 (December 31, 2025). That is 12.9% lower than the $370.70M of fiscal 2024. Figures as of 18 Nov 2026, 06:24 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Cash, fiscal 2025
$322.80M
Change on fiscal 2024
−12.9%
Highest on record
$566.85Mfiscal 2023
Lowest on record
$322.80Mfiscal 2025
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Travere Therapeutics cash on hand, in more detail

Across the 4 fiscal years on record (2022–2025), the highest was $566.85M in fiscal 2023 and the lowest $322.80M in fiscal 2025.

History · 4 fiscal years

Cash by fiscal year

Travere Therapeutics cash on hand, year by year

Travere Therapeutics (TVTX) cash on hand by fiscal year
Fiscal yearCashChangeYear ended
2025$322.80M 12.9% down
2024$370.70M 34.6% down
2023$566.85M 25.9% up
2022$450.25M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

How to read it

Cash is the cushion that pays for bad years, buybacks and acquisitions; compare it with total debt to see whether the company is a net borrower.

Cash at health care companies of similar size

Cash of Travere Therapeutics and comparable companies
CompanyCashFiscal year
MiniMed Group MMED$298.00M2026
Adaptive Biotechnologies ADPT$226.98M2025
Heartflow HTFL$176.79M2025
CRISPR Therapeutics CRSP$1.98B2025
Travere Therapeutics TVTX$322.80M2025
Option Care Health OPCH$232.62M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on TVTX

Travere Therapeutics, figure by figure

Travere Therapeutics (TVTX) overview: price, valuation and scorecardAll health care companies by market value

Travere Therapeutics cash on hand: questions and answers

How much cash does Travere Therapeutics have?

Travere Therapeutics (TVTX) held cash of $322.80M at the end of fiscal 2025 (December 31, 2025). That is 12.9% lower than the $370.70M of fiscal 2024.

What are the highest and lowest cash figures on record for Travere Therapeutics?

Across the 4 fiscal years on record (2022–2025), the highest was $566.85M in fiscal 2023 and the lowest $322.80M in fiscal 2025.

How is Travere Therapeutics's cash calculated?

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Travere Therapeutics (TVTX) cash on hand”, data as of 18 November 2026. https://funkfolio.com/stock/TVTX/cash

Underlying data: the company's filings with the SEC and Yahoo Finance.